Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802

Author:

Holtan Shernan G.1,DeFor Todd E.1,Panoskaltsis-Mortari Angela1,Khera Nandita2,Levine John E.3,Flowers Mary E. D.4,Lee Stephanie J.4,Inamoto Yoshihiro5,Chen George L.6,Mayer Sebastian7,Arora Mukta1,Palmer Jeanne2,Cutler Corey S.8,Arai Sally9,Lazaryan Aleksandr1,Newell Laura F.10,Jagasia Madan H.11,Pusic Iskra12,Wood William A.13,Renteria Anne S.3,Yanik Gregory14,Hogan William J.15,Hexner Elizabeth16,Ayuk Francis17,Holler Ernst18,Bunworasate Udomsak19,Efebera Yvonne A.20,Ferrara James L. M.3,Pidala Joseph21,Howard Alan22,Wu Juan23,Bolaños-Meade Javier24,Ho Vincent9,Alousi Amin25,Blazar Bruce R.1,Weisdorf Daniel J.1,MacMillan Margaret L.1

Affiliation:

1. Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN;

2. Mayo Clinic, Phoenix, AZ;

3. Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai, New York, NY;

4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

5. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan;

6. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY;

7. Department of Medicine, Weill Cornell Medical Center, New York, NY;

8. Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

9. Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA;

10. Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR;

11. Division of Hematology/Oncology, Stem Cell Transplantation, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;

12. Medical Oncology, Washington University Medical Center, St. Louis, MO;

13. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC;

14. Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI;

15. Blood and Marrow Transplantation Program, Mayo Clinic, Rochester, MN;

16. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;

17. Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany;

18. Blood and Marrow Transplantation Program, University of Regensburg, Regensburg, Germany;

19. Blood and Marrow Transplantation Program, Chulalongkorn University, Bangkok, Thailand;

20. Blood and Marrow Transplantation Program, The Ohio State University, Columbus, OH;

21. Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

22. National Marrow Donor Program, Minneapolis, MN;

23. The EMMES Corporation, Rockville, MD;

24. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; and

25. MD Anderson Cancer Center, Houston, TX

Abstract

Key Points High-circulating AREG (≥33 pg/mL) reclassifies additional patients into HR categories and further refines the Minnesota aGVHD risk score. Patients with aGVHD and AREG ≥33 pg/mL have lower rates of steroid response, higher NRM, and poorer OS.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3